이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Humanigen 관리
관리 기준 확인 2/4
현재 CEO에 대한 정보가 충분하지 않습니다.
주요 정보
Cameron Durrant
최고 경영자
n/a
총 보상
| CEO 급여 비율 | n/a |
| CEO 임기 | 8.3yrs |
| CEO 소유권 | n/a |
| 경영진 평균 재임 기간 | 데이터 없음 |
| 이사회 평균 재임 기간 | 7.5yrs |
최근 관리 업데이트
Recent updates
Humanigen GAAP EPS of -$0.43 misses by $0.11, revenue of $1.04M beats by $0.69M
Aug 12Humanigen plunges 57% as trial for COVID-19 therapy fails
Jul 13Humanigen jumps over 10% after peer-reviewed data on COVID-19 therapy
Jul 06Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?
Oct 30
Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?
Jul 14Humanigen begins rolling submission for lenzilumab in COVID-19 in U.K.
Jun 14Humanigen submits lenzilumab COVID-19 EUA application to FDA
May 28Humanigen is on the rise after publication of Phase 3 data for COVID-19 therapy
May 05Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price
May 05We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon
Mar 31Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?
Feb 26Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19
Jan 29Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment
Jan 11We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth
Jan 04
Humanigen secures new U.S. patent for lenzilumab
Dec 28Enrollment completed in Humanigen's early-stage ifabotuzumab study in glioblastoma multiforme
Dec 17Humanigen EPS misses by $0.16
Nov 11Humanigen up 7% on partnership with U.S. government to advance lenzilumab for COVID-19
Nov 06Humanigen executes lenzilumab licensing deal in Asia for COVID-19
Nov 03Humanigen Dosing Phase 3 Covid Patients, And Other News: The Good, Bad And Ugly Of Biopharma
Nov 01Dosing underway in lenzilumab late-stage study in COVID-19
Oct 30Dosing underway in mid-stage study of Humanigen's lenzilumab in COVID-19
Oct 29CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$54m |
| Dec 31 2022 | US$1m | US$640k | -US$71m |
| Sep 30 2022 | n/a | n/a | -US$109m |
| Jun 30 2022 | n/a | n/a | -US$152m |
| Mar 31 2022 | n/a | n/a | -US$192m |
| Dec 31 2021 | US$10m | US$640k | -US$237m |
| Sep 30 2021 | n/a | n/a | -US$235m |
| Jun 30 2021 | n/a | n/a | -US$199m |
| Mar 31 2021 | n/a | n/a | -US$153m |
| Dec 31 2020 | US$2m | US$600k | -US$90m |
| Sep 30 2020 | n/a | n/a | -US$59m |
| Jun 30 2020 | n/a | n/a | -US$31m |
| Mar 31 2020 | n/a | n/a | -US$10m |
| Dec 31 2019 | US$785k | US$600k | -US$10m |
| Sep 30 2019 | n/a | n/a | -US$10m |
| Jun 30 2019 | n/a | n/a | -US$10m |
| Mar 31 2019 | n/a | n/a | -US$9m |
| Dec 31 2018 | US$4m | US$600k | -US$12m |
| Sep 30 2018 | n/a | n/a | -US$13m |
| Jun 30 2018 | n/a | n/a | -US$18m |
| Mar 31 2018 | n/a | n/a | -US$22m |
| Dec 31 2017 | US$790k | US$600k | -US$22m |
보상 대 시장: US 시장에서 비슷한 규모의 회사에 비해 Cameron 의 총 보상이 합리적인지 여부를 입증하기에는 데이터가 부족합니다.
보상과 수익: Cameron 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Cameron Durrant (64 yo)
8.3yrs
테뉴어
US$1,099,058
보상
Dr. Cameron Durrant, MD, MBA, DRCOG, DIPCH, MRCGP, FLSW, has been Chairman of Humanigen, Inc. since January 2016. Dr. Durrant has been Chief Executive Officer at Humanigen, Inc. since March 2016 and has be...
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman | 8.5yrs | US$1.10m | 데이터 없음 | |
| Chief Scientific Officer & Director | 3.4yrs | US$661.96k | 0% $ 0 | |
| Independent Director | 6.4yrs | US$81.20k | 0.071% $ 17.0 | |
| Independent Director | 8.5yrs | US$61.60k | 0.075% $ 18.0 |
7.5yrs
평균 재임 기간
64yo
평균 연령
경험이 풍부한 이사회: HGEN.Q 의 이사회는 경험(평균 재직 기간 7.4 년)으로 간주됩니다.